Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232388 · ClinicalTrials.gov registry record
Association of PICP Serum Marker in Patients With LVSD
A clinical trial, sponsored by Texas Tech University Health Sciences Center.
- Terminated
- Registry status
- 45
- Enrollment target
NCT00232388: Clinical Trial study, sponsored by Texas Tech University Health Sciences Center.
NCT00232388 is a clinical trial that was terminated before completion, run by Texas Tech University Health Sciences Center. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00232388 was terminated before completion, sponsored by Texas Tech University Health Sciences Center.
- TERMINATED
- Registry status
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the carboxy-terminal of procollagen type I (PICP) can be a useful marker of different degrees of myocardial fibrosis.
Interventions
- PROCEDURE Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-09 |
Why NCT00232388 stopped before completion
NCT00232388 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT00232388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00232388 about?
NCT00232388 is a clinical study titled "Association of PICP Serum Marker in Patients With LVSD". The purpose of this study is to determine if the carboxy-terminal of procollagen type I (PICP) can be a useful marker of different degrees of myocardial fibrosis.
What is the current status of trial NCT00232388?
This trial is currently terminated. The enrollment target is 45 participants. The study started on 2005-09. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00232388?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT00232388?
This trial is sponsored by Texas Tech University Health Sciences Center, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia